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Extragastrointestinal Symptoms and Sensory Responses
During Breath Tests Distinguish PatientsWith Functional
Gastrointestinal Disorders
Clive H. Wilder-Smith, MD1, Asbjørn M. Drewes, MD, PhD, DMSc, EDPM, R2, Andrea Materna1 and Søren S. Olesen, MD, PhD2
INTRODUCTION: Patients with functional gastrointestinal disorders (FGIDs) are classified based on their gastrointestinal
(GI) symptoms, without considering their frequent extra-GI symptoms. This study defined subgroups of
patients using both GI and extra-GI symptoms and examined underlyingmechanisms with fructose and
lactose breath tests.
METHODS: Latent class analysis defined distinct clusters of patients with FGID based on their long-term GI and
extra-GI symptoms. Sensory and breath gas responses after fructose and lactose ingestion were
compared across symptom clusters to investigate differences in sensory function and fermentation by
intestinal microbiota.
RESULTS: Six symptomclusters were identified in 2,083patients with FGID. Clusters were characterizedmainly
by GI fermentation-type (cluster 1), allergy-like (cluster 2), intense pain-accentuated GI symptoms
(cluster 3), central nervous system (cluster 4), musculoskeletal (cluster 5), and generalized extra-GI
(cluster 6) symptoms. In the 68% of patients with complete breath tests, the areas under the curve of
GI and central nervous system symptoms after fructose and lactose ingestion differed across the
clusters (P < 0.001). The clusters with extensive long-term extra-GI symptoms had greater symptoms
after the sugars and were predominantly women, with family or childhood allergy histories.
Importantly, the areas under the curves of hydrogen and methane breath concentrations were similar
(P > 0.05) across all symptom clusters. Rome III criteria did not distinguish between the symptom
clusters.
DISCUSSION: Patients with FGID fall into clusters defined extensively by extra-GI symptoms. Greater extra-GI
symptoms are associated with evidence of generalized sensory hypersensitivity to sugar ingestion,
unrelated to intestinal gas production. Possible underlying mechanisms include metabolites
originating from the intestinal microbiota and somatization.
SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/CTG/A321, links.lww.com/CTG/A322, links.lww.com/CTG/A323
Clinical and Translational Gastroenterology 2020;11:e00192. https://doi.org/10.14309/ctg.0000000000000192
INTRODUCTION
Patients with chronic gastrointestinal (GI) symptoms butwithout
pathology identifiable by routine clinical diagnostics are classified
as having functional gastrointestinal disorders (FGIDs). FGIDs
are divided into several subgroups based on characteristic
symptoms, currently defined by the Rome criteria (1). However,
not only is the overlap between individual FGID extensive, but the
extra-GI symptoms frequently experienced by patients with
FGID also widely overlap with the symptoms of non-GI func-
tional syndromes, such as chronic pelvic pain, chronic fatigue
syndrome, or fibromyalgia (2–6). The current classifications by
symptoms result in fragmented treatment approaches and pre-
sent a barrier to the elucidation of underlying diseasemechanisms
(5–7). Recognition of the overlap in syndromes has led to
the proposition of overarching functional diagnoses, such as the
bodily distress syndrome or somatic symptom disorder and the
biopsychosocial model of irritable bowel syndrome (IBS) and
other functional disorders (8–10). Subsequently, as an exten-
sion of this model, there has been considerable research into
the “brain–gut–microbiome axis” and psychoneuroimmunology
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(11,12). Despite much discussion it remains unclear, whether the
functional syndromes constitute one syndrome with varying in-
dividual expression or whether different underlying pathologies
are lumped together by similar phenotypes.
Several population- or disease-based studies using complex
statistical modeling of symptoms associated with functional
syndromes have distinguished oligo- and multisymptomatic pa-
tient subgroups (3,4,8). The subgroups with wide multiorgan
symptoms have different demographic, cognitive, quality-of-life,
and healthcare utilization characteristics than those with few- or
single-organ symptoms (4,13). It would be of practical signifi-
cance to understand, whether the distinction between the sub-
groups is explained by different underlying mechanisms.
Although the intensity of GI symptoms might be related to vis-
ceral hypersensitivity in FGID, the link between the range of GI
and extra-GI symptoms and underlying mechanisms remains
unclear (14). Intestinal and generalized somatic hypersensitivity
and sensitization might be related to inflammatory and cognitive
causes, among others. Indeed, endogenous pain modulation by
the central nervous system (CNS) is abnormal in IBS and func-
tional dyspepsia (FD), providing a plausible explanation for
modified extra-GI sensory, autonomic, and GI neuronal function
in FGID (15–20). To further examine the relationships between
GI and extra-GI symptoms in FGID and underlying sensory
function, sugar breath tests were used, which have been shown to
evokeGI and extra-GI symptoms in patients with FGID (21). The
breath tests also allow assessment of the fermentation charac-
teristics of the intestinal microbiota.
The aims of this large, single-center study were to define dis-
tinct subgroups of patients with FGID based on their long-term
GI and extra-GI symptoms using cluster analysis and to compare
their fermentation and sensory responses after fructose and lac-
tose stimulation. Furthermore, the relationships between the
subgroups defined by cluster analysis and by Rome III criteria
were assessed. We hypothesized that extra-GI symptoms would
distinguish between groups of patients with FGID appearing
similar based on their GI symptoms and that patients with more
extra-GI symptoms would have greater symptoms provoked
during the sugar breath tests.
METHODS
Successive male and female patients older than 18 years referred
to our GI practice for investigation of FGID andwithout evidence
of organic GI disease were included. Study inclusionwas based on
a general medical evaluation, hematology, biochemistry, and
stool testing for calprotectin and pancreas elastase. In addition,
upper and lower endoscopies with biopsies were required in pa-
tients older than 40 years or in patients with diarrhea or fecal
blood. Parasite and bacterial stool cultures and abdominal ul-
trasound were performed as clinically indicated. Patients with a
documented history or evidence of organic extra-GI disease
classified as clinically significant by the investigatorwere similarly
excluded. Clinically significant disorders were defined as multi-
organ diseases potentially explaining GI symptoms, such as di-
abetes, neurological and rheumatological disorders, generalized
ischemic disorders, and systemic infectious disease. However,
patients with functional non-GI disorders, such as fibromyalgia,
chronic pelvic pain, chronic fatigue syndrome, or idiopathic ur-
ticaria, were not excluded.
An experienced gastroenterologist (C.H.W.-S.) performed all
themedical and dietary history taking and examinations. Patients
completed a standardized questionnaire focusing on their long-
term symptom profiles (Table 1), which included the specific
Rome III questions for classification of GI symptoms into FGID
groups and questions regarding childhood and family history,
dietary intolerances or allergies, central nervous (mental fog,
problems concentrating, fatigue, and depression), musculoskel-
etal (arthralgia and myalgia), dermatological (skin rash, pruritus,
and urticaria), and cardiovascular system (arrhythmias, palpita-
tions, and dizziness) symptoms (1,21–23). Some patients in-
cluded in this study were part of a previous analysis with a
different analytical focus, assessing predictive factors and the
outcome of dietary modulation and the usefulness of breath tests
(22,23).
Breath test protocol
All patients underwent fructose and lactose breath tests as
previously described (21–23). No antibiotics, colonoscopy, or
laxatives were permitted within 14 days, and patients consumed
a defined low-saccharide diet for 24 hours before the tests. Pa-
tients arrived for testing in the morning after fasting overnight,
without having smoked, chewed gum, or performed vigorous
exercise for at least 4 hours. Breath tests were performed in a
randomized sequence on 2 separate occasions at least 6 days
apart. Breath samples were collected in sealed glass tubes
(Quintron Instruments,Milwaukee,WI) before and hourly for 5
hours after ingestion of fructose 35 g or lactose 50 g dissolved in
300 mL tap water. These doses, along with the defining
thresholds shown further, were chosen for consistency with
previous studies (21–24). Hydrogen, methane, and CO2 con-
centrations were measured by BreathTracker SC (Quintron
Instruments).
Malabsorption was defined as an increase .20 ppm in hy-
drogen or .10 ppm in methane concentrations over baseline
(21,24). The following GI and extra-GI symptoms were scored
hourly and rated for intensity (05 none, 15mild, 25 intense)
concurrently with breath sampling: abdominal pain, arthralgia,
bloating, borborygmi, diarrhea, diminished concentration, epi-
gastric pain/heartburn, flatulence, fullness, headache, myalgia,
nausea, and tiredness (21–23). Intolerance was defined as an in-
crease of .2 over baseline in the aggregate GI symptom score,
which is the sum of all 8 GI symptom intensities and has a
maximum possible score of 16 (21–23).
Breath testing for evaluation of possible small intestinal bac-
terial overgrowth (SIBO) was not performed because of the in-
ability of current breath tests to conclusively demonstrate SIBO.
The study was performed in accordance with the tenets of the
latest version of the Declaration of Helsinki. Cantonal Ethics
Committee approval for anonymous data analysis was granted,
and registration was retrospectively performed in ClinTrials.gov
(NCT02085889).
Statistical analysis
The statistical analysis was performed by an author (S.S.O.)
not involved in any clinical aspects of the study and in
blinded fashion. Associations between numbers of GI and
extra-GI symptoms were analyzed using Spearman correla-
tion coefficient.
Cluster analysis and model development were performed as
follows: long-termGI and extra-GI symptoms, allergies, and self-
recognized food intolerances were assessed as being present or
not. These binary data were subjected to latent class analysis to
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identify patient groups that had similar symptom profiles, with
minimal within-group variation and maximum between-group
variation. Latent class models were fitted consecutively from a
2-cluster to an 8-cluster solution (25). The optimal number of
clusters to retain was determined by the following criteria: (i)
goodness-of-fit statistics: Bayesian information criterion and
Akaike Information Criterion; (ii) at least 5% of the total patient
sample in each cluster; and (iii) face validity of the clusters for
their clinical interpretability.
Patient characteristics and Rome III subgroups were com-
pared across the latent class analysis-derived clusters using
ANOVA and Fisher exact test. Aggregate GI and CNS symp-
toms (diminished concentration, headache, and tiredness)
after sugar ingestion were grouped separately for association
analysis with the long-term symptom clusters (21). The other
extra-GI symptoms were not considered for association anal-
ysis with the long-term symptom clusters because they were
shown to not be affected by sugar provocation (21). The areas
under the curve (AUCs) of aggregate GI and CNS symptom
scores and of the breath gas concentrations were compared
between the patient clusters using Kruskal-Wallis and Dunn
pairwise comparison tests with Bonferroni corrections for
multiple comparisons. Multivariable logistic regression mod-
els were performed to assess the associations between Rome III
subgroups and patient clusters adjusted for age and sex effects.
These results were presented as odds ratios with 95% confi-
dence intervals. A significance threshold of P , 0.05 was ap-
plied. The software package STATA version 15.1 (StataCorp
LP, College Station, TX) was used.
RESULTS
The recruitment flow of the 2,083 patients included is shown in
Figure 1. Both fructose and lactose breath tests were performed
and evaluable in 1,422 of patients (68% of complete cohort).
Patients’ characteristics are reported in Table 2.
Long-term symptom profiles
Prevalence estimates of the 18 long-term symptoms used for
cluster analysis are reported in Table 1. Across all patients, the
most prevalent GI symptomswere bloating (84%) and abdominal
pain (70%), whereas the most frequent extra-GI symptoms were
tiredness (67%) and concentration problems (35%); 55% of pa-
tients reported at least 1 allergy. The numbers of GI and extra-GI
symptoms in individual patients were positively correlated (r 5
0.35; P , 0.001).
Cluster description
The performance characteristics of the 7 different cluster
solutions for the patients’ long-term symptom profiles are
shown in Table 1 (Supplementary Digital Content 3,
http://links.lww.com/CTG/A323). The optimal model was a
6-cluster solution.
Item response probabilities for all patients and the 6 clusters
are reported in Table 1. Face validity was apparent for all clusters,
with most marked distinction in the distributions of extra-GI
symptoms. GI fermentation-type symptoms, such as bloating,
pain, stool changes, and epigastric pain/heartburn, were present
across all 6 clusters, but almost exclusively characterized cluster 1
(35% of patients). Cluster 2 (6%) was distinguished by
Table 1. Listing of symptom questionnaire items and item response probabilities for the full patient cohort and for the 6 clusters obtained
from latent class analysis
Dark gray shaded cells indicate item responses with high probabilities (67%–100%), light gray shaded cells indicate item responses with intermediate probabilities (34%–
66%), and white cells indicate item responses with low probabilities (0%–33%).
GI, gastrointestinal.
American College of Gastroenterology Clinical and Translational Gastroenterology
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Characteristics of FGID Clusters 3
additional allergy-like symptoms, cluster 3 (19%) by intense
pain-accentuated abdominal symptoms, cluster 4 (17%) by
CNS symptoms, cluster 5 (10%) bymusculoskeletal symptoms,
and cluster 6 (14%) by generalized multiorgan symptoms. The
prevalence of allergies was highest in clusters 2 (75%) and 6
(79%) and lowest in clusters 1 (45%) and 4 (40%). A radar plot
of the main symptom and history groups across the clusters is
shown Figure 2.
Patient characteristics across clusters
There were differences in age (P, 0.001) and sex (P, 0.001)
distributions across the clusters (Table 2). Men constituted
42% of cluster 1 but only 15% of cluster 6. The distribution of
ethnic subgroups was proportionate across clusters (P 5
0.91). Childhood and family histories differed across the
clusters. Childhood diarrhea, any food intolerance, and a
family history of allergy were most common in cluster 6 (all P
, 0.001), and a childhood history of any allergy was most
common in clusters 2 (62%) and 6 (50%) and least com-
mon in cluster 1 (28%) (P , 0.001) (Figure 3). There were
insignificant differences in the proportion of patients breast-
fed across the clusters (P 5 0.20).
Associations of symptom clusters with Rome subgroups
The prevalence of Rome III FGID subtypes differed numerically
between the 6 symptom clusters (Table 2), ranging from 26% to
39% for IBS (P5 0.001) and from78% to 95% for FD (P, 0.001).
Multivariate analyses confirmed the significance and in-
dependence of these associations after adjustment for sex and
age. Hence, a gradually increasing probability of IBS from
cluster 1 (reference) to cluster 6 was observed (P , 0.001)
(Figure 4). The associations with FD were less uniform and the
highest probabilities of FD were observed for clusters 3 and 6
(P, 0.001) (Figure 4). The prevalence of the Rome subgroups
of IBS and FD across the clusters is depicted in Figure 5. IBS-U
(unsubtyped) and IBS-D (diarrhea) were similar and most
common across all clusters. The FD-overlap subgroup was
most common in clusters 3 to 6, whereas functional dyspepsia
postprandial distress syndrome subtype was most common in
cluster 1.
Associations between symptom clusters and sugar breath
test responses
The AUCs of GI and CNS aggregate symptom scores after
fructose and lactose differed across the 6 clusters (all P ,
0.001). Symptom scores were consistently greatest in cluster 6
(Tables 3 and 4). The prevalence of intolerance increased from
clusters 1 to 6 with fructose (43% and 65%, respectively, P ,
0.001) and lactose (40% and 71%, respectively, P, 0.001). All
6 clusters showed similar hydrogen and methane breath con-
centration parameters and prevalence of malabsorption after
fructose and lactose ingestion (all P . 0.05) (Tables 3 and 4).
The radar plots of AUCs of the GI and CNS symptom and of
hydrogen and methane breath concentrations are shown in
Figure 1 (Supplementary Digital Content 1, http://links.lww.
com/CTG/A321). Prevalence of malabsorption in the clusters
ranged between 36% and 41% with fructose (P 5 0.91) and
between 28% and 35% with lactose (P 5 0.82). Coexistence of
Figure 1. Flowchart of patients recruited and analyzed in study. FGID, functional gastrointestinal disorder.
Clinical and Translational Gastroenterology VOLUME 11 | AUGUST 2020 www.clintranslgastro.com
FU
N
C
TI
O
N
A
L
G
I
D
IS
O
R
D
ER
S
Wilder-Smith et al.4
intolerance and malabsorption decreased significantly from
clusters 1 to 6 with fructose (64% and 48%, respectively, P ,
0.001) and lactose (71% and 56%, respectively, P, 0.001) (see
Figure 2 (Supplementary Digital Content 2, http://links.lww.
com/CTG/A322).
DISCUSSION
Distinct clusters of long-term GI and extra-GI symptoms were
defined in this large, single-center study of patients with FGID.
The phenotypic clusters ranged from limited intestinal
fermentation-like symptoms without (cluster 1) and with addi-
tional specific extra-GI (clusters 2, 4, and 5) or intense GI (cluster
3) symptoms, towhole-body symptoms (cluster 6). These clusters
differed in their symptomatic responses to sugar ingestion and
their demographic composition, but the exhaled gas concentra-
tions during breath tests were similar across all clusters. The
Rome III criteria did not distinguish reliably between the clusters
of long-term symptoms, although the probabilities of IBS and FD
varied numerically across the clusters.
Exploring symptom subgroups of functional GI disorders
Although GI symptoms are exclusively used in the current clas-
sification of subgroups of FGID, extra-GI symptoms are fre-
quently present. Several patient clusters were distinguished by
relatively organ-specific extra-GI symptoms and cluster 6 clearly
presented as a broadmultiorgan syndrome. Previous studies have
demonstrated the importance of considering extra-GI symptoms
in determining long-term outcomes in FGID (3–5,8). The evident
overlap of FGID with other functional syndromes is the basis for
the discussion onwhether the various syndromes have 1 common
cause or whether they represent an accumulation of different
disease mechanisms in the same individual (3–8,26).
Sugar breath tests indicate different disease mechanisms
In this study, a well-known mechanistic approach was chosen to
investigate the contributions ofmalabsorption, fermentation, and
sensory hypersensitivity to the overlap of symptoms
(23,24,27–29). We have recently shown that distinct GI and CNS
symptoms are provoked during breath testing with fructose and
lactose groups in patients with FGID (21). The intensity scores of
the GI and CNS symptoms correlated significantly after ingestion
of sugars, but only the severity of GI symptoms was correlated
with breath hydrogen and methane concentrations (21). This
suggests GI symptoms after the sugar ingestion are related to
mechanical distension, whereas the CNS symptoms might be
related to chemical sensory stimulation linked to fermentation
products (21,30).
This study extended these results by examining the relation-
ships between long-term symptoms and sensory and gas re-
sponses during breath tests. At the most basic level, a significant
Table 2. Patient characteristics for the full patient cohort and the 6 clusters obtained from latent class analysis
All patients
(n5 2,083)
Cluster 1
(n 5 736)
Cluster 2
(n5 117)
Cluster 3
(n5 391)
Cluster 4
(n5 348)
Cluster 5
(n5 208)
Cluster 6
(n5 283)
Mean age (yr) (SD) 39.7 (15.3) 40.6 (16.1) 40.7 (13.5) 36.7## (15.1) 35.8 ###,† (13.3) 45.5##,^^,& (15.9) 41.5^,& (14.1)
Female sex, n (%) 1,465 (70) 424 (58) 87# (74) 319### (82) 243###,^^ (70) 152###,^^ (73) 240###,^^,&,‡ (85)
Ethnicity, n (%)
Northern European 1,712 (82) 612 (83) 97 (83) 330 (84) 279 (80) 168 (81) 226 (80)
Southern European 322 (15) 109 (15) 17 (15) 54 (14) 58 (17) 33 (16) 51 (18)
Other ethnicity 49 (2) 15 (2) 3 (3) 7 (2) 11 (3) 7 (3) 6 (2)
Significance of the difference between cluster 1 and the further clusters: P, 0.05#, P, 0.01##, P , 0.001###.
Significance of the difference between cluster 2 and the further clusters; P, 0.05†.
Significance of the difference between cluster 3 and the further clusters; P, 0.01^, P , 0.001^^.
Significance of the difference between cluster 4 and the further clusters; P, 0.001&
Significance of the difference between cluster 5 and cluster 6; P, 0.001‡
Figure 2. Radar plot of main symptom groups and self-diagnosed
intolerances in the 6 long-term symptom clusters defined by latent class
analysis. Data normalized to a 0–100 scale are shown. CNS, central
nervous system.
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Characteristics of FGID Clusters 5
difference in the prevalence of fructose and lactose intolerance, as
a marker of sensory response, was evident across the phenotypic
clusters of FGID. Intolerance rates were greatest in the clusters
with the most prominent long-term GI and extra-GI symptoms,
corresponding to clusters 3 and 6. However, the prevalence of
malabsorption after the sugars was similar across all symptom
clusters. The increasing discordance between the gas and sensory
responses from oligo-to multiorgan symptomatic clusters was
confirmed using themore discriminatory analysis of the AUCs of
gas and GI symptom responses. Therefore, although gas pro-
duction and related intestinal distension might play a role in the
background fermentation-like GI symptoms common to all
Figure 3. Pediatric and family histories in the 6 long-term symptom clusters defined by latent class analysis.
Figure 4.Probabilities of being classified as having FD (upper panel) or IBS (lower panel) in the symptomclusters usingRome III criteria. Results of the age-
and sex-adjusted analysis are shown. CI, confidence interval; FD, functional dyspepsia; IBS, irritable bowel syndrome; OR, odds ratio.
Clinical and Translational Gastroenterology VOLUME 11 | AUGUST 2020 www.clintranslgastro.com
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symptom clusters, they do not explain the varying extra-GI
symptoms or the additional GI symptoms peculiar to only some
of the clusters.
Role of sensory sensitization
The greater sensory GI and CNS responses after sugar in-
gestion in the extensive multiorgan clusters are indicative of
increased sensitivity, or sensitization, extending the evidence
that mechanisms beyond malabsorption, osmotic, and fer-
mentation effects underlie symptoms in FGID (21,30–33).
Generalized sensitization, both inside and distant to the GI
tract, might be related to neuronal stimulation by metabolites
or cognitive amplification. Both mechanisms could be medi-
ated through abnormal endogenous pain modulation,
Figure 5.Prevalence of FD (upper panel) and IBS (lower panel) Rome III subtypes across the 6 long-term symptomclusters defined by latent class analysis.
FD-EP, functional dyspepsia epigastric pain subtype; FD-PDS, functional dyspepsia postprandial distress subtype; IBS, irritable bowel syndrome; IBS-C,
irritable bowel syndrome constipation subtype; IBS-D, irritable bowel syndrome diarrhea subtype; IBS-M, irritable bowel syndromemixed subtype; IBS-U,
irritable bowel syndrome unsubtyped.
Table 3. Fructose breath test results for patients with FGID according to long-term symptom profile clusters
Cluster 1
(n5 510)
Cluster 2
(n5 83)
Cluster 3
(n5 259)
Cluster 4
(n 5 251)
Cluster 5
(n5 138)
Cluster 6
(n5 181) P value
Gas
H2: baseline, PPM 3 (1–6) 3 (0–5) 3 (1–7) 3 (1–8) 3 (1–6) 3 (0–6) 0.15
H2: peak, PPM 16 (4–39) 16 (5–41) 17 (5–40) 16 (4–37) 15 (5–31) 17 (4–39) 0.85
H2: time to peak, min 120 (60–120) 120 (60–120) 120 (60–180) 120 (60–180) 120 (60–180) 120 (60–180) 0.44
H2: AUC
a 29 (4–84) 28 (6–77) 32 (6–91) 27 (2–76) 25 (4–66) 31 (6–93) 0.56
CH4: baseline, PPM 3 (2–5) 3 (2–6) 3 (2–5) 3 (2–5) 3 (2–4) 3 (2–5) 0.39
CH4: peak, PPM 4 (1–10) 4 (2–11) 5 (2–11) 5 (2–10) 4 (1–7) 5 (1–9) 0.50
CH4: time to peak, min 120 (60–120) 60 (60–120) 120 (60–180) 120 (60–180) 120 (60–180) 120 (60–180) 0.31
CH4: AUC
a 7 (0–22) 7 (0–22) 9 (1–23) 7 (0–21) 5 (1–17) 8 (1–19) 0.42
Malabsorption, n (%) 190 (37) 31 (37) 106 (41) 97 (39) 49 (36) 68 (38) 0.91
Symptoms
GI symptoms
AUC: GI aggregate symptomsa 3 (0–9) 5 (1–10) 7 (2–14) 5 (1–11) 4 (0–11) 7 (2–17) ,0.001
Intolerance, n (%) 218 (43) 41 (49) 157 (61) 124 (50) 65 (47) 117 (65) ,0.001
CNS symptoms
AUC: CNS aggregate symptomsa 0 (0–3) 1 (0–3) 1 (0–4) 1 (0–5) 2 (0–5) 3 (0–7) ,0.001
Medians and IQRs are shown.
AUC, areas under the curve; CNS, central nervous system; FGID, functional gastrointestinal disorder; GI, gastrointestinal; IQR, interquartile range.
aAUCs are baseline corrected.
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previously demonstrated to be abnormal in FGID with sensory
testing and functional MRI studies (15,18–20). Intestinal hy-
persensitivity to distension and chemical stimulation as well as
generalized hypersensitivity have been confirmed in sub-
groups of patients with IBS and FD (14,18,34–41). The data of
this study suggest that sensitization to mechanical and
chemical stimulation by gaseous or nongaseous pronoci-
ceptive metabolites of fructose and lactose are implicated in
the wide spectrum of GI and extra-GI clinical symptoms in
patients with FGID. The activity and composition of intestinal
microbiota differ between IBS and controls, providing a po-
tential mechanism for sensitization by the formation of
proinflammatory and pronociceptive compounds, including
monoamines, biogenic amines, short-chain fatty acids, neu-
ropeptides, neurotransmitters, and especially advanced gly-
cation end products (32,42,43). Several of the implicated
pathways could explain multiorgan sensory hypersensitivity,
including aberrant histaminergic and mast cell activation (31).
Emerging data suggest changes in the intestinal microbiome
also exist in FD (44).
Somatization is a further potential explanation for hypersen-
sitivity in FGID (14,26,45,46). Somatization and sensory sensi-
tization are associated, and distinction currently mainly relies on
clinical judgment and questionnaires (47).
The relevance of early-life stressors and genetic factors in
adult multiorgan symptoms in FGID is established and might
explain the observed association with childhood chronic di-
arrhea, allergy or food intolerance, and a family history of al-
lergy in cluster 6 compared with the fermentation-like cluster
1 (48).
Symptom cluster association with IBS, FD, and demographics
Symptom associations in FGID have mostly been studied in pa-
tients with IBS, which is largely defined by changes in bowel habit
rather than a broad range of chronicGI symptoms. In this analysis,
the clusters with a greater number of GI and extra-GI symptoms
weremore frequently associated with FD than with IBS. The Rome
III FD-overlap subtype was most common in these clusters,
reflecting both pain and postprandial aspects, rather than
mainly postprandial fullness and early satiety. Exclusion of
patients with FD from mechanistic studies of FGID, therefore,
excludes patients with a greater degree of sensitization and
constitutes a clear selection bias. There was no clear variation
in Rome III IBS subtypes across the symptom clusters, im-
plying that the Rome III criteria do not capture the underlying
differences in patient clusters.
There was a difference in sex distribution between the symp-
tom clusters, with more women in the multiorgan symptom
clusters. Although the studied cohort was not population based, it
is unlikely that this difference is random in such a large single-
center study. This sex discrepancy against the background of a
uniform prevalence ofmalabsorption across all symptom clusters
indicates factors affecting sensory function or the metabolism of
the intestinal microbiota are likely operative. Sex differences have
been described for all of these factors, but their review is beyond
the scope of this article (49,50).
Limitations
Specific psychological factors and further sensory tests were not
additionally assessed in the mechanistic study of sensitization,
omitting potentially relevant modulating factors in FGID.
Table 4. Lactose breath test results for patients with FGID according to long-term symptom profile clusters
Cluster 1
(n5 510)
Cluster 2
(n5 83)
Cluster 3
(n5 259)
Cluster 4
(n5 251)
Cluster 5
(n5 138)
Cluster 6
(n 5 181) P value
Gas
H2: baseline, PPM 3 (1–6) 2 (0–5) 4 (1–7) 3 (1–8) 3 (1–6) 3 (1–6) 0.04
H2: peak, PPM 9 (2–36) 10 (3–39) 9 (2–29) 5 (1–31) 1 (9–45) 2 (9–41) 0.32
H2: time to peak, min 180 (120–180) 180 (120–300) 240 (120–300) 180 (60–300) 180 (60–240) 180 (120–240) 0.17
H2: AUC
a 13 (0–73) 16 (1–76) 11 (0–57) 7 (0–61) 10 (0–90) 11 (0–73) 0.24
CH4: baseline, PPM 3 (2–5) 3 (2–5) 3 (2–5) 3 (2–6) 3 (2–4) 3 (2–4) 0.27
CH4: peak, PPM 3 (1–9) 4 (1–11) 3 (1–9) 2 (0–9) 3 (1–8) 3 (1–10) 0.27
CH4: time to peak, min 180 (60–240) 180 (60–240) 180 (60–240) 120 (0–240) 180 (60–240) 180 (60–240) 0.10
CH4: AUC
a 5 (0–19) 7 (0–28) 4 (0–19) 2 (0–16) 4 (0–17) 5 (0–21) 0.06
Malabsorption, n (%) 162 (32) 29 (35) 79 (31) 70 (28) 45 (33) 54 (30) 0.82
Symptoms
GI symptoms
AUC: GI aggregate symptomsa 4 (0–10) 6 (1–14) 6 (0–14) 5 (0–13) 4 (0–13) 9 (2–19) ,0.001
Intolerance, n (%) 204 (40) 41 (49) 138 (53) 131 (52) 67 (49) 129 (71) ,0.001
CNS symptoms
AUC: CNS aggregate symptomsa 1 (0–4) 1 (0–5) 2 (0–6) 2 (0–7) 3 (0–7) 5 (0–8) ,0.001
Medians and interquartile ranges (IQR) are shown.
AUC, areas under the curve; CNS, central nervous system; FGID, functional gastrointestinal disorder; GI, gastrointestinal.
aAUCs are baseline corrected.
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However, the influences of psychological factors and intestinal
distension have been extensively reported in earlier studies
(26,39,45). Furthermore, patients were not specifically ques-
tioned regarding recall of an acute infection at the onset of chronic
symptoms. This would have been useful, even though such recall
is often unreliable (51). SIBO is observed across a wide range of
conditions and overlaps extensively with sugar intolerances. Its
independent role in intolerances remains unclear, noninvasive
testing is controversial, and consequently, we chose not to per-
form breath testing for SIBO in this study (52). Successive pa-
tients referred to our practice were enrolled in this study,
conferring a selection bias, which would have been avoidedwith a
population-based sample. However, the enriched recruitment
seen in secondary- and tertiary-care patients enabled us to in-
clude a large number of male and female patients in the multi-
organ symptom clusters, allowing a more balanced and in-depth
analysis. This approach has been used successfully in previous
studies (53). Furthermore, all patients were referred to and
assessed by the same 2 staff in a single center, eliminating the
substantial confounders inherent to the pooling of patients from
different countries, centers, discontinuous recruitment periods,
and using varying investigative protocols.
No separate discovery and validation cohorts were analyzed,
raising the possibility of statistical overfit. Although validation in
the same setting is not meaningful, application to a different
setting and population might also lead to different results owing
to the influence of endogenous and exogenous factors.
The questionnaire used in this study has not been externally
validated but derives from the symptoms most commonly listed
by our patients and quantified by a simple Likert scale. It has
established high face validity across several studies and includes
the standardized Rome classification questions (21–23). There is
a clear need for a validated questionnaire for capture of extra-GI
symptoms in patients with FGID.
CONCLUSIONS
Cluster analysis of long-term GI and extra-GI symptom profiles
inmore than 2,000 patients with FGID defined 6 distinct patient
clusters. The cluster phenotypes varied from fermentation-like
GI symptoms, to a combination of wider GI and focused extra-
GI symptoms, to whole-body symptoms. Intestinal gas pro-
duction or malabsorption of fructose or lactose measured by
breath gas analysis did not provide an explanation for the dif-
ferent symptom clusters, in distinction to the sensory responses
indicative of sensitization. Possible mechanisms for generalized
hypersensitivity include metabolites originating from the in-
testinal microbiota and somatization. This study highlights the
importance of the inclusion of extra-GI symptoms in the study
and classifications of FGID.
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Study Highlights
WHAT IS KNOWN
3 Patients with FGIDs are classified according to their GI
symptoms.
3 Intestinal hypersensitivity exists in a substantial patient
subset.
WHAT IS NEW HERE
3 Patients with FGIDs fall into phenotypic clusters defined
extensively by extra-GI symptoms.
3 Patients with greater extra-GI symptoms have evidence of
generalized sensory hypersensitivity to sugar ingestion
unrelated to intestinal gas production.
TRANSLATIONAL IMPACT
3 Extra-GI symptoms should be included in future studies and
classifications of FGID.
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